摘要
当前,我国医药产业生态格局和行业运行规则正在剧变,中药产业面临新的挑战,以临床价值、科学价值为核心的科技创新驱动,成为中药产业高质量发展的关键推动力。科技竞争力集中体现了中成药产品的临床价值和科学价值,通过科技竞争力评价,有助于形成正确的价值导向,催生行业内生动力。项目组基于公开数据和评价模型,进行中药大品种科技竞争力评价,编制《中药大品种科技竞争力报告(2018版)》,全景式展示了中药大品种科技竞争力概况。本文包含全品类百强榜、非注射百强榜、各省区排行榜第一名、各治疗领域前三名等榜单。具有科技竞争力优势的中药大品种,正成为引领中药产业高质量发展的中坚力量。
At present,the ecological pattern and operation rules of the pharmaceutical industry in China are changing dramatically,the traditional Chinese medicine industry is facing new challenges.The scientific and technological innovation driven by clinical and scientific value has become the main driving force for the high-quality development of Chinese medicine industry.Scientific and technological competitiveness embodies the clinical and scientific value of Chinese patent medicine products.Through the evaluation of scientific and technological competitiveness,it is helpful to form the correct value orientation,and promote the endogenous power of the industry.Based on the open data and evaluation model,the project team carried out the evaluation of the scientific and technological competitiveness of large varieties of traditional Chinese medicine,and compiled the “Report on the Scientific and Technological Competitiveness of Large Varieties of Traditional Chinese Medicine(2018 Edition)”,which panoramically displayed the general situation of the scientific and technological competitiveness of large varieties of traditional Chinese medicine.The top 100 list of the whole category,the top 100 list of non-injection,the top one of the provinces and regions,and the top three of the treatment fields are included in this article.Large varieties of traditional Chinese medicine(TCM)with the advantage of scientific and technological competitiveness are becoming the backbone force leading the high-quality development of TCM industry.
作者
李耿
李振坤
郭宇博
程煜华
李文珊
刘立营
张秀梅
杨洪军
LI Geng;LI Zhen-kun;GUO Yu-bo;CHENG Yu-hua;LI Wen-shan;LIU Li-ying;ZHANG Xiu-mei;YANG Hong-jun(China Academy of Chinese Medical Sciences,Beijing 100070,China;Big Brand Traditional Chinese Medicine League,Beijing 100070,China;China Association of Chinese medicine,Beijing 100029,China;Institute of Scientific and Technical Information of China,Beijing 100038,China;Wanfang Data Co.,Ltd.,Beijing 100038,China;Institute of Chinese Materia Medica/China Academy of Chinese Medical Sciences,Beijing 100070,China)
出处
《中国现代中药》
CAS
2019年第1期1-19,共19页
Modern Chinese Medicine
基金
中国科协项目(2018-64)
国家中医药管理局项目(GZY-KJS-2018-016-09
GZY-FJS-2018-612)
关键词
中药大品种
科技竞争力
产品评价
大数据
评价模型
指标体系
科技因子
big brand traditional Chinese medicine
scientific and technological competitiveness
scientific and technological evaluation
big data
evaluation model
evaluating indicator
scientific factor score
作者简介
第一作者:李耿,博士,国家卫健委中日友好医院副主任药师,江西中医药大学客座教授,从事中药质量及产业科技发展研究。兼任中药大品种联盟执行主编、中国中医药信息学会中药调配与监测分会副会长、中国中药协会艾草专业委员会副主任委员、中华中医药学会青年委员会副秘书长、世界中医药联合会临床用药安全专业委员会副秘书长。参与10余项国家科研项目,发表20余篇学术论文及10余篇报刊文章,参与编写《中药大品种科技竞争力报告》等行业研究报告,国家“十三五创新教材”《中医药学概论》副主编,国家住院中医师规培教材《临床常用方剂与中成药》副主编,申请国家发明专利 7项,4项已经授权;通信作者:杨洪军,研究员,研究方向:基于整合药理学的中药新药设计与大品种培育;Tel:(010)57730848,E-mail:hongjun0420@vip.sina.com,本刊编委,医学博士,博士生导师,获得卫计委有突出贡献的中青年专家、中国科协"求是杰出青年成果转化奖"荣誉。主要从事基于整合药理学策略的中药新药设计与大品种培育研究。兼职任中药大品种联盟秘书长等。主持国家自然科学基金重点项目、国家重大新药创制重大专项等多项国家级课题,参与“十三五”中医药科技创新专项规划等多项战略性研究课题;牵头编制《中药大品种科技竞争力报告》;获省部级一等奖(排名第1)等多项奖励;发表学术论文100余篇,其中SCI论文 30余篇,主编著作5部;主持开发中医传承辅助平台,获得软件著作权3项,获得发明专利5项。
